ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,095Medicare Part D Prescriptions Filled, Including Refills

Rank: 141 out of 2094

$875K Total Retail Price of All Prescriptions

Rank: 148 out of 2094

351 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 351 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 9,975 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

38% of this provider’s prescriptions were for brand-name drugs, compared to an average of 32%.

Prescription Price

$79 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
FUROSEMIDE 481 413 1 6
METOPROLOL TARTRATE 295 242 2 10
SIMVASTATIN 266 254 3 1
AMLODIPINE BESYLATE 259 249 4 2
POTASSIUM CHLORIDE 251 224 5 24
DIOVAN 251 220 5 13
LEVOTHYROXINE SODIUM 248 218 7 3
WARFARIN SODIUM 217 189 8 11
OMEPRAZOLE 197 188 9 4
CRESTOR 197 184 9 15
METOPROLOL SUCCINATE 196 191 11 9
ATORVASTATIN CALCIUM 190 173 12 5
OXYCODONE-ACETAMINOPHEN 173 143 S2 13 40
PRAVASTATIN SODIUM 173 169 13 18
BYSTOLIC 167 158 15 83
METFORMIN HCL 152 140 16 8
DONEPEZIL HCL 149 149 17 20
NAMENDA 142 142 18 32
ISOSORBIDE MONONITRATE ER 137 131 19 57
CLOPIDOGREL 135 116 20 22
DIGOXIN 127 112 21 51
GABAPENTIN 115 91 22 23
NEXIUM 114 111 23 16
PLAVIX 113 104 24 38
LISINOPRIL 111 108 25 7
ZETIA 109 91 26 79
ZOLPIDEM TARTRATE 106 94 27 14
BENICAR 102 98 28 108
DIOVAN HCT 99 86 29 28
LIPITOR 98 78 30 39
DOXAZOSIN MESYLATE 98 87 30 120
ALENDRONATE SODIUM 94 94 32 30
CLONIDINE HCL 92 80 33 62
PANTOPRAZOLE SODIUM 81 69 34 37
EXFORGE 79 79 35 105
AMLODIPINE BESYLATE-BENAZEPRIL 79 79 35 58
ENOXAPARIN SODIUM 78 74 37 173
PREDNISONE 73 69 38 54
EXELON 72 72 39 111
AZITHROMYCIN 71 61 40 27
FENOFIBRATE 69 66 41 104
ADVAIR DISKUS 68 62 42 36
TRAMADOL HCL 68 56 42 33
SYNTHROID 67 67 44 44
MUPIROCIN 66 65 45 117
TRICOR 62 38 46 99
FENTANYL 61 61 S2 47 68
SERTRALINE HCL 60 34 48 26
FAMOTIDINE 60 59 48 34
GLIMEPIRIDE 52 41 50 31
CARVEDILOL 52 39 50 19
JANUMET 52 34 50 86
DILTIAZEM 24HR CD 52 50 50 110
LOSARTAN POTASSIUM 51 43 54 17
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.